Data sources and searches
We conducted a systematic literature search to identify RCTs which
assessed the safety and efficacy of omalizumab in AR. Two reviewers
independently searched MEDLINE (through PubMed) and the Cochrane Central
Register of Controlled Trials (CENTRAL) from inception on September 30,
2020 and inconsistencies were resolved by a third reviewer. A search in
PubMed was performed using the following algorithm “(’omalizumab’ OR
’anti-IgE’ OR ‘anti-immunoglobin E’) AND (’rhinitis’ OR ’allergic
rhinitis’) AND (random OR random* OR trial OR ”randomised controlled
trial” OR ”randomized controlled trial” OR ”clinical trial”)” and in
CENTRAL using the terms “(’omalizumab’ OR ’anti-IgE’ OR
‘anti-immunoglobin E’) AND (‘rhinitis’ OR ‘allergic rhinitis’)”.
All randomized trials that assessed subcutaneous omalizumab as treatment
or pretreatment in patients with AR were considered eligible. All
nonrandomized and quasi-randomized trials were excluded. We also
excluded studies that assessed clinical outcomes unrelated to rhinitis,
studies using an anti-IgE other than omalizumab, and studies which were
not RCTs.